Shares of Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.04, with a volume of 5,025 shares.
Mateon Therapeutics Price Performance
The business has a fifty day moving average of $0.03 and a 200-day moving average of $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Read More
- Five stocks we like better than Mateon Therapeutics
- Why Are Stock Sectors Important to Successful Investing?
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- What is the Nikkei 225 index?
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- With Risk Tolerance, One Size Does Not Fit All
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
